Jornal de Vasculite

Use of Anti TNF-α Therapy in Systemic Vasculitis

Abstract

Talal Al-Mteri, Fatma Al-shaiki, Shahd Hafiz, Rabab Taha, Omar Fathaddien and Hani Almoallim

There are several vascultic disorders still labeled as difficult-to-treat cases. Effective treatment for those patients is warranted to reduce the mortality and morbidity that resulting from these disorders. An extensive review for the literatures that addressed using of ant TNF-alpha in several vascultic disorders was conducted. Use of anti TNFalpha agents is a promising modality in several vascultic disorders. Despite lacking well-conducted randomized controlled trials, more open-label studies are required to examine in-depth the safety and efficacy of those agents.